Fxol is thought to contribute to the reduction in the viability of aggressive estrogen-independent tumor growth by inhibiting nuclear translocation and members of transcriptional activity in the NF-κB signaling pathway [94]. The gene discussed is NFKB1; the disease is neoplasm.